XML 50 R38.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segment Reporting (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
Summary of Segment Information | The table below provides segment information about the Group:
|  | Year Ended December 31, |
|  |  | 2024 |  |  |  | 2023 |  |  |  | 2022 |
|  | $000s |  |  | $000s |  |  | $000s |
Revenue |  |  | 43,258 |  |  |  | 31,643 |  |  |  | 21,655 |
Less: |  |  |  |  |  |  |  |  |
Cost of sales |  |  | (11,810 | ) |  |  | (12,867 | ) |  |  | (13,463 | )
Contracted development costs (a) |  |  | (42,902 | ) |  |  | (35,048 | ) |  |  | (24,322 | )
Personnel research and development costs (b) |  |  | (20,503 | ) |  |  | (19,468 | ) |  |  | (17,187 | )
Other R&D costs (c) |  |  | (4,478 | ) |  |  | (2,421 | ) |  |  | (2,041 | )
General & administrative expenses |  |  | (26,884 | ) |  |  | (26,222 | ) |  |  | (25,682 | )
Tax expense |  |  | (845 | ) |  |  | (956 | ) |  |  | (688 | )
Other segment items (d) |  |  | 18,855 |  |  |  | 11,111 |  |  |  | 11,394 |
Consolidated net loss |  |  | (45,309 | ) |  |  | (54,228 | ) |  |  | (50,334 | )
(a) Contracted development costs primarily consist of costs incurred under agreements with CROs and investigative sites that conduct its preclinical studies and clinical trials; costs related to manufacturing active pharmaceutical ingredients and drug products for its preclinical studies and clinical trials; and costs for materials used for in-house research and development activities. (b) Personnel R&D costs primarily consist of salaries and personnel-related costs for personnel performing R&D activities or managing those activities that have been out-sourced; and consultants’ costs associated with target selection, preclinical and clinical research activities, and the progression of programs towards clinical trials. (c) Other R&D costs include associated facility costs, equipment and other overheads that are directly attributable to R&D and depreciation of capital assets used for research and development activities. (d) The other segment items include foreign currency gain (loss), net, benefit from R&D credit, and other income/ (expense), net inclusive of bank interest receivable and accretion on U.S. Treasury Bills.
Summary of Group's Assets and Revenues by Location | An analysis of the group’s assets and revenues by location is shown below:
|  | U.S.A. |  |  | U.K. |  |  | Germany |  |  | Total |
|  | $000s |  |  | $000s |  |  | $000s |  |  | $000s |
Non-current assets |  |  |  |  |  |  |  |  |  |  |  |
As at December 31, 2023 |  |  | - |  |  |  | 4,467 |  |  |  | 11,831 |  |  |  | 16,298 |
As at December 31, 2024 |  |  | - |  |  |  | 4,103 |  |  |  | 11,166 |  |  |  | 15,269 |
Revenue analysis for the year ended December 31, 2022 |  |  |  |  |  |  |  |  |  |  |  |
Research collaboration |  |  | - |  |  |  | 20,940 |  |  |  | - |  |  |  | 20,940 |
Royalties |  |  | - |  |  |  | - |  |  |  | 715 |  |  |  | 715 |
|  |  | - |  |  |  | 20,940 |  |  |  | 715 |  |  |  | 21,655 |
Revenue analysis for the year ended December 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |
Research collaboration |  |  | - |  |  |  | 30,934 |  |  |  | - |  |  |  | 30,934 |
Royalties |  |  | - |  |  |  | - |  |  |  | 709 |  |  |  | 709 |
|  |  | - |  |  |  | 30,934 |  |  |  | 709 |  |  |  | 31,643 |
Revenue analysis for the year ended December 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |
Research collaboration |  |  | - |  |  |  | 43,114 |  |  |  | - |  |  |  | 43,114 |
Royalties |  |  | - |  |  |  | - |  |  |  | 144 |  |  |  | 144 |
|  |  | - |  |  |  | 43,114 |  |  |  | 144 |  |  |  | 43,258 |

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration